1765: Influenza Vaccination Recommendations, Tirzepatide for CV Risk Reduction, New Drugs for Breast Cancer, Melanoma, and Hearing Loss

The objective is to meet the need of health care professionals for unbiased, reliable and timely information on new and older drugs, including the mechanisms of action, pharmacokinetics, clinical trials, adverse effects, interactions, dosages and routes of administration of the drugs discussed. The objectives will also meet the needs for unbiased, reliable and timely information on treatment of major diseases. Through this program, The Medical Letter expects to provide the prescribing health care community with educational content that they can use to make independent and informed therapeutic choices in their practice. Activity participants will read and assimilate unbiased reviews of FDA-approved and off-label uses of drugs and drug classes. Participants will be able to select and prescribe, or confirm the appropriateness of the prescribed usage of the drugs and other therapeutic modalities discussed, with specific attention to clinical evidence of effectiveness, adverse effects and patient management.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Target Specialties

Cross-Specialty

Relevant across 6 specialties.

Pricing

Included with subscription

Listed by the provider

Enduring / On-demand
Credit · Up to 2 credits
MOC · Up to 2 points
Included in subscription

Released

Oct 1, 2026
Last day to claim credit

Oct 1, 2027 12 months left

1765: Influenza Vaccination Recommendations, Tirzepatide for CV Risk Reduction, New Drugs for Breast Cancer, Melanoma, and Hearing Loss

More from Medical Letter, The

Related courses